Genprex and Roche Diagnostics launched collaboration work aimed at validating biomarker assays using Genprex’s TROP2 approach in non-small cell lung cancer. Genprex said it plans to potentially integrate TROP2 expression as a patient-selection marker for NSCLC clinical studies, while Roche will validate assays using its TROP2 antibody. The collaboration focuses on assay validation studies that can support consistent companion-test-like performance across trials, a practical issue for developers when biomarker expression drives eligibility and response interpretation. For Genprex, the effort may streamline TROP2-driven study enrollment and improve comparability across clinical sites. For Roche Diagnostics, the work expands its role in translational biomarker assurance for oncology trials.